0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab FREE

Florent Grange, MD, PhD; Eve Maubec, MD; Martine Bagot, MD, PhD; Marie Beylot-Barry, MD, PhD; Pascal Joly, MD, PhD; Stéphane Dalle, MD; Emmanuel Delaporte, MD; Olivier Dereure, MD, PhD; Hervé Bachelez, MD, PhD; Béatrice Vergier, MD, PhD; Tony Petrella, MD; Michel D’Incan, MD, PhD
Arch Dermatol. 2009;145(3):329-330. doi:10.1001/archdermatol.2009.23.
Text Size: A A A
Published online

In contrast with most primary cutaneous B-cell lymphomas, primary cutaneous large B-cell lymphomas, leg type (PCLBCLs-LT) are often life-threatening.13 Owing to their occurrence in elderly patients (many patients aged >80 years), these lymphomas have often been treated with radiotherapy alone or palliative chemotherapies, resulting in 5-year survival rates around 50%.13 Recently, the addition of rituximab to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) (R-CHOP) was found to prolong survival in 60- to 80-year-old patients with nodal diffuse large B-cell lymphomas (DLBCLs).4,5 Although this result was not directly applicable to older patients with PCLBCL-LT, it rapidly led to a significant shift in French practice, consisting in using the classic R-CHOP regimen in patients younger than 80 years and in generally good condition, and less intensive combinations of rituximab and polychemotherapies (R-PCTs) in the oldest and/or frailest patients. To our knowledge, such an approach has never been evaluated.

All consecutive patients registered in the French Study Group of Cutaneous Lymphomas for a PCLBCL-LT and treated with R-PCT between January 2002 and June 2007 were included in the study. Medical records were reviewed and comprehensive data were collected, including baseline characteristics, type of R-PCT regimen, adverse events, response to therapy, relapse, extracutaneous progression, subsequent therapies, and final status. Follow-up data were collected from referent dermatologists and from general practitioners, when necessary, until the final evaluation period (January 1 to March 31, 2008). The study was approved by the institutional review board of Reims University Hospital, Reims, France.

Twenty-five patients, aged 44 to 96 years (median age, 76 years), were included in the study (Table). For 11 cases (1, 2, 3, 5, 6, 9, 10, 12, 21, 24, and 25), preliminary data and short-term outcomes were previously reported.2 Twenty patients had lesions located on the leg at presentation, whereas 5 had a PCLBCL-LT at sites other than the leg. Seventeen patients (group 1) received R-PCT as first-line therapy, and 8 (group 2) received R-PCT as second-line therapy for refractory skin lesions (n = 5) or visceral dissemination (n = 3) to the central nervous system (case 21), lung and bone (case 22), or bone marrow and mesenteric nodes (case 16). The R-PCT was R-ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) in 1 case, a standard R-CHOP regimen in 14 cases, an R-CHOP regimen with lower doses (R-miniCHOP) in 7 cases, and a less intensive R-PCT without anthracycline in 4 cases.

Table Graphic Jump LocationTable Baseline Characteristics, Therapy, and Follow-up Data for 25 Patients Treated With R-PCT for PCDLBCL-LT

All 17 patients in group 1 and 6 of 8 in group 2 achieved a complete response, but 10 experienced relapse in the skin (n = 8), the skin and lymph nodes (n = 1), or the central nervous system (n = 1). Four patients had multiple successive cutaneous relapses. Treatment of relapses included surgery (1 case), radiotherapy (4 cases), rituximab (1 case), ibritumomab tiuxetan (1 case), and/or various chemotherapies (4 cases). No patient was lost to follow-up. After a 33-month median follow-up, 20 patients were alive (including 13 in complete remission), 3 had died of lymphoma, and 2 had died of unrelated causes. The 3-year disease-specific survival rate was 87%.

Nine patients (36%) had at least 1 grade 3 or higher adverse event, including grade 3 (n = 2) or grade 4 (n = 5) neutropenia, grade 4 thrombocytopenia (n = 1), grade 4 neutropenic sepsis (n = 1), grade 3 cardiac failure (n = 1), grade 3 pneumonia (n = 1), and grade 3 venous thrombosis (n = 1; this patient had a catheter). One patient died of neutropenic septicemia.

These 25 patients treated with R-PCT were compared with a historic series of 47 patients with PCLBCL-LT who received other therapies only, as detailed in a previous study.2 The 2 groups did not differ by classic prognostic factors,2 including age (median ages, 76 vs 78 years) (P = .30), location of skin lesions, clinical stage at diagnosis, performance status, or lactic dehydrogenase level. However, the percentage of patients who achieved a complete response (92% vs 64%) (P = .01) and the 3-year specific survival rates (87% vs 50%) (P = .004) were much higher in patients treated with R-PCT.

We report for the first time to our knowledge a complete response rate greater than 90% and a 3-year survival rate greater than 80% in patients with PCLBCL-LT. Despite the retrospective design of the study, these results and the comparison with a historic series of patients treated earlier with other therapies only strongly suggest that the prognosis of these life-threatening lymphomas may be dramatically improved by the use of age-adapted R-PCT. Response and survival rates in our patients were higher than those reported in elderly patients with DLBCL treated with standard R-CHOP,4,5 suggesting that PCLBCL-LT could in fact be less aggressive than their systemic counterparts. Patients older than 80 years (n = 9; 36%) and those with a poor general condition received less-intensive R-PCT with overall favorable results. Main adverse events in the entire series were neutropenia and consecutive infections, suggesting that granulocyte-colony stimulating factor should be systematically used when treating PCLBCL-LT with R-PCT, as recommended in at-risk elderly patients with DLBCL.6 Recurrences were frequent but were often limited to the skin and were responsive to subsequent treatments. These data provide a basis for prospective clinical trials. Further studies could compare standard R-CHOP to less intensive R-PCT and/or investigate the optimal number of R-PCT cycles and the role of a maintenance therapy with rituximab to prevent recurrences.

ARTICLE INFORMATION

Correspondence: Dr Grange, Department of Dermatology, Hôpital Robert Debré, avenue du général Koenig, 51092 Reims CEDEX, France (fgrange@chu-reims.fr).

Author Contributions:Study concept and design: Grange. Acquisition of data: Grange, Maubec, Bagot, Beylot-Barry, Joly, Dalle, Delaporte, Dereure, Bachelez, Vergier, Petrella, and D’Incan. Analysis and interpretation of data: Grange. Drafting of the manuscript: Grange. Critical revision of the manuscript for important intellectual content: Maubec, Bagot, Beylot-Barry, Joly, Dalle, Delaporte, Dereure, Bachelez, Vergier, Petrella, and D’Incan. Statistical analysis: Grange. Study supervision: Grange.

Financial Disclosure: None reported.

Additional Contributions: Alain Delmer, MD, PhD, provided useful advice and hematologic expertise.

Willemze  RJaffe  ESBurg  G WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105 (10) 3768- 3785
PubMed Link to Article
Grange  FBeylot-Barry  MCourville  P Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007;143 (9) 1144- 1150
PubMed Link to Article
Senff  NJHoefnagel  JJJansen  PM Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007;25 (12) 1581- 1587
PubMed Link to Article
Coiffier  BLepage  EBrière  J CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346 (4) 235- 242
PubMed Link to Article
Feugier  PVan Hoof  ASebban  C Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23 (18) 4117- 4126
PubMed Link to Article
Thieblemont  CCoiffier  B Lymphoma in older patients. J Clin Oncol 2007;25 (14) 1916- 1923
PubMed Link to Article

Figures

Tables

Table Graphic Jump LocationTable Baseline Characteristics, Therapy, and Follow-up Data for 25 Patients Treated With R-PCT for PCDLBCL-LT

References

Willemze  RJaffe  ESBurg  G WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105 (10) 3768- 3785
PubMed Link to Article
Grange  FBeylot-Barry  MCourville  P Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007;143 (9) 1144- 1150
PubMed Link to Article
Senff  NJHoefnagel  JJJansen  PM Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007;25 (12) 1581- 1587
PubMed Link to Article
Coiffier  BLepage  EBrière  J CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346 (4) 235- 242
PubMed Link to Article
Feugier  PVan Hoof  ASebban  C Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23 (18) 4117- 4126
PubMed Link to Article
Thieblemont  CCoiffier  B Lymphoma in older patients. J Clin Oncol 2007;25 (14) 1916- 1923
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,104 Views
16 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy